NYSE:LCI - Lannett Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $6.50
  • Forecasted Upside: 38.89 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.68
▼ -0.3 (-6.02%)
1 month | 3 months | 12 months
Get New Lannett Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LCI and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LCI

Average Price Target: $6.50
▲ +38.89% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Lannett in the last 3 months. The average price target is $6.50, with a high forecast of $7.00 and a low forecast of $6.00. The average price target represents a 38.89% upside from the last price of $4.68.

Hold

The current consensus among 3 contributing investment analysts is to hold stock in Lannett. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
12/27/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
3/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
6/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
9/22/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
12/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
3/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
5/20/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
6/19/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021Roth CapitalLower Price TargetNeutral$7.50 ➝ $7.00High
11/3/2020Raymond JamesReiterated RatingHoldHigh
8/27/2020Roth CapitalBoost Price TargetNeutral$9.00 ➝ $11.00Medium
8/27/2020BMO Capital MarketsReiterated RatingHold$6.00High
8/27/2020Raymond JamesReiterated RatingHoldHigh
8/17/2020Raymond JamesReiterated RatingHoldHigh
9/18/2019SunTrust BanksBoost Price TargetHold$10.00 ➝ $14.00Medium
8/29/2019SunTrust BanksBoost Price TargetHold$10.00High
8/28/2019Roth CapitalReiterated RatingNeutralHigh
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$9.00Medium
12/13/2018Raymond JamesReiterated RatingHoldHigh
8/20/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$19.00 ➝ $8.00High
8/20/2018Raymond JamesDowngradeOutperform ➝ Market Perform$43.00High
8/20/2018Craig HallumDowngradeBuy ➝ HoldLow
8/20/2018Roth CapitalDowngradeBuy ➝ Neutral$23.00 ➝ $27.50High
5/9/2018OppenheimerReiterated RatingHoldLow
3/22/2018OppenheimerReiterated RatingHoldHigh
2/8/2018BMO Capital MarketsLower Price TargetMarket Perform ➝ Market Perform$22.00 ➝ $21.00Low
2/7/2018Roth CapitalSet Price TargetBuy$25.00Low
2/7/2018OppenheimerReiterated RatingHoldLow
1/24/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$21.00Medium
12/11/2017OppenheimerReiterated RatingHoldLow
11/13/2017BMO Capital MarketsBoost Price TargetMarket Perform$20.00 ➝ $22.00N/A
8/24/2017BMO Capital MarketsReiterated RatingMarket Perform$26.00 ➝ $20.00High
8/23/2017OppenheimerReiterated RatingHoldHigh
8/22/2017Roth CapitalSet Price TargetBuy$27.00High
8/14/2017Deutsche Bank AktiengesellschaftLower Price TargetHold$23.00 ➝ $19.00Medium
7/17/2017Deutsche Bank AktiengesellschaftReiterated RatingHold$22.00 ➝ $23.00High
6/8/2017OppenheimerReiterated RatingHoldHigh
5/3/2017Robert W. BairdReiterated RatingOutperform$18.00Medium
5/2/2017OppenheimerReiterated RatingHoldMedium
5/2/2017Roth CapitalSet Price TargetBuy$27.00Medium
5/1/2017BMO Capital MarketsInitiated CoverageMarket Perform$29.00Medium
3/25/2017OppenheimerReiterated RatingHoldHigh
2/2/2017Roth CapitalSet Price TargetBuy$28.00N/A
12/6/2016OppenheimerReiterated RatingHoldN/A
11/6/2016Roth CapitalSet Price TargetBuy$34.00N/A
10/18/2016Deutsche Bank AktiengesellschaftReiterated RatingHold$32.00 ➝ $26.00N/A
8/24/2016Raymond JamesBoost Price TargetOutperform$31.00 ➝ $43.00N/A
7/12/2016OppenheimerReiterated RatingHoldN/A
6/29/2016Deutsche Bank AktiengesellschaftInitiated CoverageHold$26.00N/A
(Data available from 6/20/2016 forward)
Lannett logo
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was founded in 1942 and is headquartered in Philadelphia, Pennsylvania.
Read More

Today's Range

Now: $4.68
Low: $4.65
High: $4.94

50 Day Range

MA: $4.72
Low: $4.17
High: $5.33

52 Week Range

Now: $4.68
Low: $4.12
High: $10.70

Volume

1,079,873 shs

Average Volume

833,892 shs

Market Capitalization

$193.97 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.13

Frequently Asked Questions

What sell-side analysts currently cover shares of Lannett?

The following Wall Street analysts have issued research reports on Lannett in the last twelve months: BMO Capital Markets, Raymond James, Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for LCI.

What is the current price target for Lannett?

2 Wall Street analysts have set twelve-month price targets for Lannett in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 38.9%. Roth Capital has the highest price target set, predicting LCI will reach $7.00 in the next twelve months. BMO Capital Markets has the lowest price target set, forecasting a price of $6.00 for Lannett in the next year.
View the latest price targets for LCI.

What is the current consensus analyst rating for Lannett?

Lannett currently has 3 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LCI, but not buy more shares or sell existing shares.
View the latest ratings for LCI.

What other companies compete with Lannett?

How do I contact Lannett's investor relations team?

Lannett's physical mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company's listed phone number is 215-333-9000. The official website for Lannett is www.lannett.com.